Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY1003803 formulations in plaque psoriasis
NCT02940002Phase 1Completed
- Sponsor
- Bayer
- Start
- Oct 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BAY1003803 in plaque psoriasis (6 arms), sponsored by Bayer. Primary endpoint: Change in infiltrate thickness from day 1 to day 29. Started Oct 2016; status: completed.
02
Drugs
BAY1003803
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02940002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940002.